Ordering from the Americas?Switch to the US store
We don't ship to your country yet. We ship across Europe and the Americas. You can keep browsing.

Peptency Academy · Guide

Peptide patches: transdermal and microneedle delivery in research

What is a peptide patch, and what does the research say about moving a peptide through skin?

A transdermal patch is a layered product, with a backing and normally an adhesive, that carries an active substance through intact skin and into the body. Source sentencecontaining one or more active substances to be applied to the intact skin for systemic absorption. This is normally formulated with pressure-sensitive adhesives that assure the adhesion of the preparation to the skin.1 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014 A microneedle patch is a micron scale hybrid between a transdermal patch and the hypodermic format: an array of tiny projections that open short routes through the outer skin. Source sentenceMicroneedles (MN) are the micron-scale hybrid between transdermal patches and hypodermic syringes.2 Drug Deliv Transl Res 2022 Published work loads peptides into microneedle patches and measures loading, mechanical strength, release and exposure in skin and animal models. Human studies exist for a parathyroid hormone fragment and for abaloparatide. Source sentenceAbstract, methods: phase 1 and phase 2 studies of the coated patch in volunteers and in post-menopausal women; abaloparatide phase 1b abstract; semaglutide formulation abstract.3 Pharm Res 20114 Clin Drug Investig 20215 AAPS PharmSciTech 2026 The central design problem is molecular size. Skin absorption is argued to need a molecular weight under 500 dalton, and a peptide such as semaglutide sits far above that line. Source sentenceWe argue that the molecular weight (MW) of a compound must be under 500 Dalton to allow skin absorption.6 Exp Dermatol 2000

Version 1Edited 35 sources

Regulatory content shown for: EU and UK.

Known, not known, contested

Known

  • A 2000 review argued that skin absorption needs a molecular weight under 500 dalton, reasoning from contact allergens, topical drugs and transdermal systems. Source sentencevirtually all common contact allergens are under 500 Dalton, larger molecules are not known as contact sensitizers6 Exp Dermatol 2000
  • Microneedle designs fall into solid, coated, hollow and polymer groups. Polymer microneedles can dissolve, stay intact, or form a hydrogel. Source sentenceMultiple microneedles designs have been fabricated i.e. solid, coated, hollow, and polymer microneedles.2 Drug Deliv Transl Res 2022
  • A coated microneedle patch of parathyroid hormone (1-34) and a solid microstructured system for abaloparatide have each reached human studies. Source sentencePhase 1 ZP-PTH patch delivery demonstrated a rapid PTH plasma pulse profile3 Pharm Res 20114 Clin Drug Investig 2021
  • Semaglutide, liraglutide, exenatide and exendin-4 have each been loaded into dissolving microneedle patches in preclinical studies. Source sentenceThis study focuses on the development and characterization of DMN arrays formulated with a polymeric blend of hyaluronic acid, PETOX, and L-arginine, designed for the transdermal delivery of SMG.5 AAPS PharmSciTech 20267 Drug Deliv Transl Res 20258 Pharm Res 20149 Sci Rep 2018
  • A 2026 review of 24 patch dietary supplements and one gel sold as natural GLP-1 products found no certificate of analysis posted for any of them. Source sentenceWe identified 24 transdermal patch dietary supplement products and 1 transdermal gel product ... No certificates of analysis were posted10 Ann Pharmacother 2026

Not known

Contested

  • A 2025 review calls published data on the skin permeability of GHK-Cu and palmitoyl-GHK insufficient, while a 2015 study measured copper peptide crossing human skin that microneedles had punctured. Source sentencethe published information on their skin permeability, effectiveness, physicochemical properties and so on is insufficient13 Bioimpacts 202514 Pharm Res 2015

Why skin is a hard route for a peptide

  • The outer skin layer, the stratum corneum, is the barrier. First generation transdermal systems have been used for small, lipophilic molecules. Source sentenceAbstract, second sentence: first-generation systems and small, lipophilic molecules.15 Nat Biotechnol 2008
  • Semaglutide has an average molecular mass of 4,114 dalton, about eight times the 500 dalton line. Source sentencePubChem computed properties: molecular formula C187H291N45O59, molecular weight about 4114 g/mol.16 PubChem, semaglutide (CID 56843331)6 Exp Dermatol 2000
  • GHK-Cu, at 402.92 dalton, sits under the line, yet in one study almost no peptide or copper crossed intact human skin in 9 hours. Source sentenceIn 9 h, 134 ± 12 nanomoles of peptide and 705 ± 84 nanomoles of copper permeated though the microneedle treated human skin, while almost no peptide or copper permeated through intact human skin.14 Pharm Res 201517 PubChem, GHK-Cu (CID 71587328)
  • The authors tie the poor absorption of GHK-Cu to its hydrophilicity. Source sentenceHowever, its skin absorption remains challenging due to its hydrophilicity.14 Pharm Res 2015
  • Conventional chemical permeation agents have been described as almost unable to move a peptide across the epidermal barrier. Source sentenceTransdermal delivery of peptide drugs is almost impossible with conventional penetration enhancers because of epidermal barrier function.7 Drug Deliv Transl Res 2025
Where each route acts in the skin
  • Stratum corneum
  • Viable epidermis
  • Dermis
  1. Passive patch
  2. Chemical permeation agent
  3. Iontophoresis
  4. Solid microneedles
  5. Coated microneedles
  6. Dissolving microneedles
  7. Hollow microneedles
  8. Hydrogel forming microneedles

Not to scale. Each route is described and cited in the list that follows.

The routes in plain terms

Passive patch
A passive patch relies on diffusion through intact skin, with an adhesive layer, a backing and a liner. Source sentenceTransdermal patches are designed to provide a controlled delivery of the active substance(s) through the skin, principally by diffusion1 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014
Chemical permeation agent
Chemical permeation agents loosen the barrier. They belong to the second generation of transdermal systems, with ultrasound and iontophoresis, and have reached clinical products. Source sentenceSecond-generation delivery systems using chemical enhancers, noncavitational ultrasound and iontophoresis have also resulted in clinical products15 Nat Biotechnol 2008
Iontophoresis
Iontophoresis uses an applied electrical current to drive hydrophilic and charged molecules across skin. Current, pH and concentration are its key settings. Source sentenceIontophoresis provides a mechanism to enhance the penetration of hydrophilic and charged molecules across the skin.18 Adv Drug Deliv Rev 2004
Solid microneedles
Solid microneedles make openings in the skin first. A formulation or patch goes on the openings afterwards. Source sentenceSolid microneedles a patch is applied after creating a hole in the skin2 Drug Deliv Transl Res 2022
Coated microneedles
Coated microneedles carry the drug as a layer on the surface of the microneedle. Source sentenceDrugs are coated on the surface of Coated microneedles2 Drug Deliv Transl Res 2022
Dissolving microneedles
Dissolving microneedles hold the peptide inside a polymer that dissolves in the skin. An exenatide hyaluronate patch released its load within 2 minutes in one study. Source sentencerapidly dissolved to release encapsulated drug within 2 min8 Pharm Res 2014
Hollow microneedles
Hollow microneedles carry a liquid formulation through a bore, a design close to a hypodermic but much shorter. Source sentenceHollow microneedles are shorter in length but similar to hypodermic needles and have pore for infusion of liquid formulation of the drug.2 Drug Deliv Transl Res 2022
Hydrogel forming microneedles
Hydrogel forming microneedles are a polymer class listed beside dissolving and non-dissolving types. Source sentencePolymer microneedles can be of different types like dissolving, non-dissolving or hydrogel-forming made up of polymers.2 Drug Deliv Transl Res 2022
Osmotic hollow patch
A wearable osmotic patch with three hollow microneedles released exenatide in rats and mice for 24 hours, in a study of sustained release. Source sentenceThe OMN patch released the peptide drug exenatide in rats and mice for 24 hours19 Sci Transl Med 2024

Reference cases: parathyroid hormone, abaloparatide and insulin

  • A coated microneedle patch of parathyroid hormone (1-34) was studied in phase 1 for application site, wear time and amount, then in phase 2 against a placebo patch and a parenteral reference. Source sentenceAbstract, methods: phase 1 pharmacokinetic studies varied application site, wear time and amount in volunteers aged 40 to 85; phase 2 compared patch levels with a placebo patch and a reference product.3 Pharm Res 2011
  • In phase 1 the patch gave a quick plasma pulse of the hormone: time to peak was about three times shorter than for the reference route. Source sentencePhase 1 ZP-PTH patch delivery demonstrated a rapid PTH plasma pulse profile with T(max) 3 times shorter and apparent T(1/2) 2 times shorter3 Pharm Res 2011
  • An abaloparatide solid microstructured transdermal system reached phase 1b in 22 postmenopausal participants, with systemic exposure as the primary endpoint. Median time to peak on day 1 was 0.33 hours. Source sentenceThe primary endpoint was systemic exposure to abaloparatide ... the median time to reach maximum concentration (Tmax) for abaloparatide-sMTS was 0.33 h4 Clin Drug Investig 2021
  • Insulin microneedle systems have been reviewed across hollow, dissolving, hydrogel forming and glucose responsive patches, with clinical studies grouped by study phase. Source sentenceincluding hollow MNs, dissolving MNs, hydrogel MNs, and glucose-responsive MN patches20 Drug Deliv Transl Res 2022
  • A 2008 review placed microneedles and thermal ablation in clinical trials for insulin, parathyroid hormone and influenza vaccine. Source sentenceMicroneedles and thermal ablation are currently progressing through clinical trials for delivery of macromolecules and vaccines, such as insulin, parathyroid hormone and influenza vaccine.15 Nat Biotechnol 2008
  • A 2012 review described a decade of microneedle research on protein and peptide patches that had yet to result in a single product. Source sentencea decade research efforts have yet to result in a single product21 Curr Pharm Biotechnol 2012

GLP-1 analogues in microneedle studies

  • A semaglutide dissolving patch built from hyaluronic acid, a polymer called PETOX and L-arginine reached a fracture force of 3.47 N per microneedle and released its load over 12 hours in the lab. Source sentencerobust mechanical strength (3.47 N/needle; fracture force), excellent Parafilm M insertion (> 50% at 450 μm depth), and drug release over 12 h.5 AAPS PharmSciTech 2026
  • L-arginine was added as a stabilising excipient for the peptide in that patch. Source sentenceunique stabilization of SMG by incorporating L-arginine5 AAPS PharmSciTech 2026
  • A polyvinyl alcohol patch with 15 by 15 microneedles held 29 ± 2 µg of semaglutide per patch. The apparent delivered amount in rat skin was 18 ± 2 µg, or 63 ± 3 percent (n = 3). Source sentenceSema-MNs contained 29 ± 2 μg semaglutide per patch, with an apparent delivered amount of 18 ± 2 μg (63 ± 3%; n = 3)22 Int J Pharm 2026
  • More than 90 percent of the labelled cargo left that patch within 30 minutes, and rat skin barrier function approached baseline within 4 to 6 hours. Source sentencereleased more than 90% of the Sema-Cy5-associated cargo within 30 min ... skin barrier function approached baseline within 4-6 h22 Int J Pharm 2026
  • A hyaluronic acid and aminoclay nanocomposite bound semaglutide by electrostatic interaction, gave 0.37 N per microneedle and stayed stable at 25 °C in storage. Source sentenceSema-AC/HA10 demonstrated a mechanical strength of 0.37 ± 0.020 N/needle and retained stable physicochemical and morphological properties at 25°C during storage.23 Int J Nanomedicine 2025
  • A liraglutide patch with pure drug tips loaded up to 2.21 ± 0.14 mg in 0.9 cm², nearly two orders of magnitude more than conventional dissolving patches of the same size. Source sentenceThe MN patch could load up to 2.21 ± 0.14 mg of liraglutide in a patch size of 0.9 cm2, which was nearly two orders of magnitude higher than that obtained with conventional MN patches of the same size.7 Drug Deliv Transl Res 2025
  • In rats and minipigs that patch reached relative bioavailability of 69.8 and 46.3 percent against a parenteral reference, with delivery variability under 6.8 percent. Source sentenceachieved relative bioavailability of 69.8% and 46.3% compared to S.C. injection in rats and minipigs, respectively7 Drug Deliv Transl Res 2025
  • An exenatide hyaluronate patch kept the peptide's activity through fabrication and one month of storage. Skin barrier function recovered within 10 to 12 hours. Source sentenceThe EXT preserved its pharmacological activity during fabrication and one-month storage. ... skin's barrier properties disrupted by MNs recovered within 10-12 h.8 Pharm Res 2014

GHK-Cu and cosmetic peptides

  • With microneedles, 134 ± 12 nanomoles of GHK peptide and 705 ± 84 nanomoles of copper crossed human skin in 9 hours. Crossing depended on the force used to apply the microneedles. Source sentenceThe depth and percentage of microneedle penetration were correlated with application forces, which in turn influenced the extent of enhancement in the skin permeability of GHK-Cu.14 Pharm Res 2015
  • A 2026 evidence map grades GHK-Cu delivery studies on claimed loading, molar copper occupancy, labile copper, species resolved release, stability and objective outcome. Source sentenceDelivery studies were extracted against a fixed matrix comprising formulation, claimed loading, molar copper occupancy, labile copper, species-resolved release, factorial controls, stability/manufacturability, and objective outcome.24 Pharmaceutics 2026
  • Acetyl hexapeptide-8 is hydrophilic and relatively large, which limits its permeability through the stratum corneum. Source sentenceDue to its hydrophilic nature and relatively large molecular size, AH-8 faces limited permeability through the lipophilic stratum corneum25 Int J Mol Sci 2025
  • Review strategies for peptide skin delivery include nanocarriers, metal complexation, cell penetrating peptides and chemical modification. Source sentencenanocarrier development advances for the topical delivery of peptides ... and other strategies, such as metal complexation, cell-penetrating peptides, and synthetic modification26 Crit Rev Ther Drug Carrier Syst 2022

Stability: patch against lyophilised vial

  • Freeze-drying is used because it raises the storage stability of peptides that are only marginally stable in solution. Source sentenceThe solidification performed at lower temperature significantly improves storage stability of proteins, peptides, antibiotics, vaccines, and liposomes, which are marginally stable in aqueous solutions.27 Adv Exp Med Biol 2018
  • Exendin-4 kept up to 98.3 ± 1.5 percent of its activity in dissolving microneedles, but only after thermal, chemical and physical fabrication parameters had been tuned. Source sentenceoptimising the parameters involved in DMN fabrication retained the activity of Ex-4 by up to 98.3 ± 1.5%9 Sci Rep 2018
  • After 3 months, the amount of exenatide left in that patch did not differ between storage at 40 °C and at -20 °C. Source sentencethe remaining EXT amount was not significantly different under storage at 40 °C and -20 °C for 3 months28 Int J Pharm 2023
  • The authors of a 2026 semaglutide patch study name loss of peptide activity and stability as challenges that remain. Source sentencechallenges persist regarding loss of therapeutic activity and stability of peptide5 AAPS PharmSciTech 2026

Patch and lyophilised vial side by side

Microneedle patch as studied in the literature, and the lyophilised vial, on three questions
QuestionMicroneedle patch, as studiedLyophilised vial
Stability in storageStability depends on the matrix and on fabrication. In one exenatide patch the remaining peptide did not differ between 40 °C and -20 °C over 3 months. Source sentencethe remaining EXT amount was not significantly different under storage at 40 °C and -20 °C for 3 months28 Int J Pharm 2023Freeze-drying is the standard answer for peptides that are marginally stable in solution. Source sentenceThe solidification performed at lower temperature significantly improves storage stability of proteins, peptides ... which are marginally stable in aqueous solutions.27 Adv Exp Med Biol 2018
Amount controlLoading and delivered amount differ: 29 µg loaded and 18 µg apparently delivered in rat skin for one semaglutide patch. Source sentence29 ± 2 μg semaglutide per patch, with an apparent delivered amount of 18 ± 2 μg (63 ± 3%; n = 3)22 Int J Pharm 2026Net content is reported per lot on the certificate of analysis. Source sentenceNet content is one of the three lines of the Peptency certificate of analysis.29 Peptency lab results and certificate of analysis page
How it is testedMechanical strength, insertion, release, skin permeation and delivered amount, plus extract purity and identity. Source sentenceAbstract: critical quality attributes include delivered amount and puncture performance.30 J Control Release 202531 Int J Pharm 2016HPLC purity, LC-MS identity and net content on the certificate of analysis. Source sentenceLab results page: HPLC purity, LC-MS identity, net content.29 Peptency lab results and certificate of analysis page

How a patch is tested

  • The EMA guideline on transdermal patches, adopted on 23 October 2014, discusses in vitro drug release, adhesion and skin permeation testing. Source sentenceIn particular, in vitro performance testing with respect to drug release, adhesion and skin permeation is discussed1 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014
  • In vitro permeation work normally uses diffusion cells with 0.5 to 2 cm² of skin. The most common design is the Franz type static cell with two chambers. Source sentenceIn vitro permeation studies are usually performed using diffusion cells, with a skin diffusion area between 0.5-2 cm2. ... The most common diffusion cells are Franz-type (static) cells1 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014
  • Because biological skin varies, one group proposed Parafilm M layers as a test membrane. A 196 microneedle array with 600 µm microneedles released between 40 and 180 µg of cargo in 6 hours. Source sentenceDissolving MN arrays containing 196 needles (600 μm needle height) were inserted into a single layer of PF ... releasing between 40 and 180 μg of their cargos after 6h.31 Int J Pharm 2016
  • Patches usually hold more active substance than they deliver, so loading and delivered amount are different numbers. Source sentenceTransdermal patches usually contain an excess of active substance than that delivered1 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014
  • A 2025 white paper from international stakeholders lists more than twenty critical quality attributes for a microneedle product form. Source sentenceAbstract: more than twenty potential critical quality attributes (CQAs) are identified for the product form.30 J Control Release 2025

What is sold as a peptide patch

  • A 2026 review found 24 transdermal patch dietary supplement products and one gel sold as natural GLP-1 products. They listed 7 ± 4 natural ingredients on average. Source sentenceWe identified 24 transdermal patch dietary supplement products and 1 transdermal gel product with an average of 7 ± 4 natural ingredients10 Ann Pharmacother 2026
  • No certificates of analysis were posted for those products, and many carried no FDA disclaimer. Source sentenceNo certificates of analysis were posted, many products lacked the Food and Drug Administration disclaimer10 Ann Pharmacother 2026
  • Peptency publishes a certificate of analysis for each lot, covering HPLC purity, LC-MS identity and net content. Source sentenceVerify a Peptency lot number and read how each certificate of analysis is checked: HPLC purity, LC-MS identity, net content.29 Peptency lab results and certificate of analysis page

European Union: the EMA guideline and cosmetics law

EU

  • The EMA guideline on quality of transdermal patches applies to patches for systemic delivery. Cutaneous patches not meant for systemic absorption are out of its scope. Source sentenceCutaneous patches (where the active substance is not intended to be systemically absorbed) are out of the scope of this guideline.1 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014
  • EU cosmetics law defines a cosmetic product by contact with external body parts and a purpose of cleaning, perfuming, changing appearance, protecting, keeping in good condition or correcting body odour. Source sentence‘cosmetic product’ means any substance or mixture intended to be placed in contact with the external parts of the human body ... with a view exclusively or mainly to cleaning them, perfuming them, changing their appearance, protecting them, keeping them in good condition or correcting body odours32 Regulation (EC) No 1223/2009, Article 2, as retained on legislation.gov.uk
  • A substance intended to enter the body, for example by ingestion or implant, is not a cosmetic product under the same article. Source sentencea substance or mixture intended to be ingested, inhaled, injected or implanted into the human body shall not be considered to be a cosmetic product32 Regulation (EC) No 1223/2009, Article 2, as retained on legislation.gov.uk

United Kingdom: the borderline between cosmetic and medicine

UK

  • In Great Britain a product that fits both the cosmetic definition and the medicinal definition is classified as a medicinal product. (reported by MHRA, read through a search summary) Source sentenceMHRA guidance: a product that falls within both the cosmetic and the medicinal product definition is classified as a medicinal product.33 MHRA, borderline products guidance for Great Britain

Microneedle patches as a product form

  • A 2025 white paper expects a microneedle and active substance sold as one unit to be classed as a combination or medicinal product, and calls the regulatory science for this product form immature, with limited explicit guidance. Source sentenceAbstract, first sentences: regulatory science for this emerging product form is immature and explicit guidance is limited.30 J Control Release 2025

Milestones in the published record

  1. A review argues skin absorption needs a molecular weight under 500 dalton (PubMed 10839713). Source sentenceWe argue that the molecular weight (MW) of a compound must be under 500 Dalton to allow skin absorption.6 Exp Dermatol 2000
  2. A review of iontophoretic delivery includes peptides and proteins (PubMed 15019750). Source sentenceThe iontophoretic delivery of peptides and proteins is also discussed.18 Adv Drug Deliv Rev 2004
  3. A review sorts transdermal systems into three generations and puts microneedles in trials for insulin and parathyroid hormone (PubMed 18997767). Source sentenceThird-generation delivery systems target their effects to skin's barrier layer of stratum corneum using microneedles15 Nat Biotechnol 2008
  4. A coated microneedle patch of parathyroid hormone (1-34) is reported through phase 1 and 2 studies (PubMed 20567999). Source sentencePhase 1 PK studies ... Phase 2 was conducted in post-menopausal women3 Pharm Res 2011
  5. A review states a decade of microneedle work has yet to produce a single peptide patch product (PubMed 22201589). Source sentencea decade research efforts have yet to result in a single product21 Curr Pharm Biotechnol 2012
  6. Exenatide dissolving patches: activity kept through fabrication and one month of storage (PubMed 24867426). Source sentenceThe EXT preserved its pharmacological activity during fabrication and one-month storage.8 Pharm Res 2014
  7. Copper peptide GHK crosses human skin punctured by microneedles, and almost none crosses intact skin (PubMed 25690343). The EMA patch quality guideline comes into effect in June 2015. Source sentencealmost no peptide or copper permeated through intact human skin14 Pharm Res 20151 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014
  8. Abaloparatide solid microstructured system reaches phase 1b with 22 participants (PubMed 33638863). Source sentence22 healthy postmenopausal women aged 50-85 years with low BMD4 Clin Drug Investig 2021
  9. A wearable osmotic microneedle patch releases exenatide for 24 hours in rodents (PubMed 39602507). Source sentencereleased the peptide drug exenatide in rats and mice for 24 hours19 Sci Transl Med 2024
  10. A pure tip liraglutide patch loads 2.21 mg in 0.9 cm², and a white paper lists more than twenty quality attributes for microneedle product forms (PubMed 38619705, 39603537). Source sentenceload up to 2.21 ± 0.14 mg of liraglutide in a patch size of 0.9 cm27 Drug Deliv Transl Res 202530 J Control Release 2025
  11. Three semaglutide microneedle formulation papers and a review of 24 supplement patches appear (PubMed 42393458, 42906796, 41480958). Source sentenceSemaglutide dissolving microneedle formulation study, 2026.5 AAPS PharmSciTech 202622 Int J Pharm 202610 Ann Pharmacother 2026

Do peptide patches work?

For microneedle patches the record is formulation work, animal measurements and two human programmes, one for parathyroid hormone and one for abaloparatide. It answers how much peptide a patch holds and releases, which is a narrower question than whether a patch works. Source sentenceAbstract, methods and results: phase 1 and 2 patch studies of a parathyroid hormone fragment.3 Pharm Res 20114 Clin Drug Investig 202122 Int J Pharm 2026 For a patch without microneedles, a PubMed search on 11 November 2026 found no controlled delivery study of GHK-Cu, BPC-157 or semaglutide. Source sentenceQuery run on 11 November 2026; no controlled study in the results.12 PubMed search for transdermal patch without microneedles, 11 November 2026

Is there a semaglutide patch?

Semaglutide has been formulated as a dissolving microneedle patch in three preclinical papers from 2025 and 2026. They report 29 µg loaded per patch in one, and fracture forces of 3.47 N and 0.37 N per microneedle in the other two. Source sentenceSema-MNs contained 29 ± 2 μg semaglutide per patch22 Int J Pharm 20265 AAPS PharmSciTech 202623 Int J Nanomedicine 2025 The papers measure loading, strength, release and results in rat or porcine skin. None of them is a clinical study. Source sentenceAbstract: in vitro and preclinical studies in rats of semaglutide hyaluronic acid and aminoclay microneedles.23 Int J Nanomedicine 20255 AAPS PharmSciTech 2026 The patches sold as natural GLP-1 products in the 2026 review listed natural ingredients such as berberine, glutamine, cinnamon and pomegranate. Source sentenceaverage of 7 ± 4 natural ingredients (berberine, glutamine/glutamate, cinnamon, and pomegranate most listed)10 Ann Pharmacother 2026

Do GHK-Cu patches deliver copper peptide through skin?

Measured copper peptide crossing skin comes from microneedle work. Through punctured human skin, 134 ± 12 nanomoles crossed in 9 hours, against almost none through intact skin. Source sentenceIn 9 h, 134 ± 12 nanomoles of peptide and 705 ± 84 nanomoles of copper permeated though the microneedle treated human skin, while almost no peptide or copper permeated through intact human skin.14 Pharm Res 2015 A 2025 review of topical GHK describes its skin permeability as insufficiently documented. Source sentencethe published information on their skin permeability, effectiveness, physicochemical properties and so on is insufficient13 Bioimpacts 2025

Why does molecular size matter for a peptide patch?

Size is one limit and polarity is another. GHK-Cu is under 500 dalton but hydrophilic, and acetyl hexapeptide-8 is described as both hydrophilic and relatively large. Source sentenceits skin absorption remains challenging due to its hydrophilicity14 Pharm Res 201525 Int J Mol Sci 2025

Is a transdermal patch the same as a microneedle patch?

A transdermal patch relies on diffusion through intact skin. A microneedle patch opens routes through the outer skin first, and most peptide patch research uses microneedles. Source sentenceTransdermal patches are designed to provide a controlled delivery of the active substance(s) through the skin, principally by diffusion1 EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/20142 Drug Deliv Transl Res 2022

Does a peptide patch need a certificate of analysis?

A patch holds a small, fixed amount of peptide, for example 29 µg in one semaglutide study, so a content figure per patch is the number that matters. Source sentenceSema-MNs contained 29 ± 2 μg semaglutide per patch22 Int J Pharm 2026 That figure comes from extracting the peptide from the patch and assaying it, the same step that a purity and identity check starts from. Source sentenceAn accurate and reliable method was established to determine the needle drug loading proportion in sCT-DMNAs.34 AAPS PharmSciTech 202035 J Pharm Anal 2015

Published examples with IDs

  1. Analytical only (no biological model)Experimental dermatology 2000

    The molecular weight limit for skin absorption

    Design
    Narrative review and argument from contact allergens, topical drugs and transdermal systems
    Molecule
    Chemical compounds in general not established

    PubMed 10839713DOI

  2. In vitro or ex vivoPharmaceutical research 2015

    GHK-Cu and copper crossing intact and microneedle punctured human skin over 9 hours

    Design
    Ex vivo human skin and porcine models with microneedle pre-puncture, plus cell safety work
    Population or model
    Human skin in vitro, porcine skin, cell culture
    Molecule
    GHK-Cu exact
    Duration
    9 hours

    PubMed 25690343DOI

  3. In vitro or ex vivoAAPS PharmSciTech 2026

    Fracture force, Parafilm insertion depth, release over 12 hours and ex vivo porcine skin insertion

    Design
    Formulation and characterisation of dissolving microneedles with hyaluronic acid, PETOX and L-arginine
    Population or model
    Parafilm M, porcine skin ex vivo
    Molecule
    Semaglutide exact

    PubMed 42393458DOI

  4. RodentInternational journal of pharmaceutics 2026

    Loading per patch, apparent delivered amount, release within 30 minutes and skin barrier recovery

    Design
    Polyvinyl alcohol dissolving microneedles made by vacuum assisted molding, tested in rat skin
    Population or model
    Rats
    Molecule
    Semaglutide exact
    n
    3
    Comparator
    Unloaded microneedle controls

    PubMed 42906796DOI

  5. RodentInternational journal of nanomedicine 2025

    Fracture force of 0.37 N per microneedle, stability at 25 °C and systemic exposure versus free drug microneedles

    Design
    Hyaluronic acid and aminoclay nanocomposite microneedles tested for strength, storage stability and exposure in rats
    Population or model
    Rats
    Molecule
    Semaglutide exact

    PubMed 41030572DOI

  6. RodentDrug delivery and translational research 2025

    Loading up to 2.21 mg per 0.9 cm², delivered amount, relative bioavailability and local skin response

    Design
    Dissolving microneedle patch with pure drug tips, pharmacokinetics in rats and minipigs
    Population or model
    Rats and minipigs
    Molecule
    Liraglutide related form

    PubMed 38619705DOI

  7. RodentPharmaceutical research 2014

    Dissolution within 2 minutes, skin barrier recovery in 10 to 12 hours and activity after one month of storage

    Design
    Hyaluronate dissolving microneedles: strength, insertion, dissolution, storage and exposure
    Population or model
    Rats
    Molecule
    Exenatide related form
    Duration
    1 month storage

    PubMed 24867426DOI

  8. RodentInternational journal of pharmaceutics 2023

    Retained exenatide after 9 weeks at high temperature and 3 months at 40 °C and -20 °C

    Design
    Stratified dissolving microneedles with dextran, polyvinyl alcohol and zinc, stored at high temperature
    Population or model
    Rats
    Molecule
    Exenatide related form
    Duration
    9 weeks and 3 months

    PubMed 36934885DOI

  9. Human, randomisedPharmaceutical research 2011

    Plasma hormone profile by application site, wear time and amount

    Design
    Phase 1 pharmacokinetic studies and a phase 2 study of a coated microneedle patch
    Population or model
    Volunteers aged 40 to 85 and post-menopausal women
    Molecule
    Parathyroid hormone (1-34) related form
    Comparator
    Placebo patch and a reference product

    PubMed 20567999DOI

  10. Human, uncontrolledClinical drug investigation 2021

    Systemic exposure of abaloparatide, time to peak and local tolerability

    Design
    Single arm open label phase 1b study of a solid microstructured transdermal system
    Population or model
    Postmenopausal women aged 50 to 85
    Molecule
    Abaloparatide related form
    n
    22
    Duration
    29 days

    PubMed 33638863DOI

  11. Analytical only (no biological model)International journal of pharmaceutics 2016

    Release of model cargos from 196 microneedle arrays over 6 hours

    Design
    Parafilm M pouch release test compared with Franz cell methodology for dissolving arrays
    Population or model
    Parafilm M membrane
    Molecule
    Model cargos not established

    PubMed 26621687DOI

  12. Analytical only (no biological model)Journal of controlled release : official journal of the Controlled Release Society 2025

    Classification, nomenclature and more than twenty critical quality attributes

    Design
    White paper by international stakeholders on regulatory science of microneedle product forms
    Molecule
    Microneedle product forms not established

    PubMed 39603537DOI

  13. Analytical only (no biological model)The Annals of pharmacotherapy 2026

    Count of patch products, listed ingredients and posted certificates of analysis

    Design
    Review of patch dietary supplement products sold as natural GLP-1 products
    Molecule
    Supplement patch products not established
    n
    25

    PubMed 41480958DOI

Sources

  1. 1EMA, Guideline on quality of transdermal patches, EMA/CHMP/QWP/608924/2014 accessed 11 Nov 2026
  2. 2Drug Deliv Transl Res 2022 accessed 11 Nov 2026
  3. 3Pharm Res 2011 accessed 11 Nov 2026
  4. 4Clin Drug Investig 2021 accessed 11 Nov 2026
  5. 5AAPS PharmSciTech 2026 accessed 11 Nov 2026
  6. 6Exp Dermatol 2000 accessed 11 Nov 2026
  7. 7Drug Deliv Transl Res 2025 accessed 11 Nov 2026
  8. 8Pharm Res 2014 accessed 11 Nov 2026
  9. 9Sci Rep 2018 accessed 11 Nov 2026
  10. 10Ann Pharmacother 2026 accessed 11 Nov 2026
  11. 11PubMed search for peptide patch and lyophilised stability, 11 November 2026 accessed 11 Nov 2026
  12. 12PubMed search for transdermal patch without microneedles, 11 November 2026 accessed 11 Nov 2026
  13. 13Bioimpacts 2025 accessed 11 Nov 2026
  14. 14Pharm Res 2015 accessed 11 Nov 2026
  15. 15Nat Biotechnol 2008 accessed 11 Nov 2026
  16. 16PubChem, semaglutide (CID 56843331) accessed 11 Nov 2026
  17. 17PubChem, GHK-Cu (CID 71587328) accessed 11 Nov 2026
  18. 18Adv Drug Deliv Rev 2004 accessed 11 Nov 2026
  19. 19Sci Transl Med 2024 accessed 11 Nov 2026
  20. 20Drug Deliv Transl Res 2022 accessed 11 Nov 2026
  21. 21Curr Pharm Biotechnol 2012 accessed 11 Nov 2026
  22. 22Int J Pharm 2026 accessed 11 Nov 2026
  23. 23Int J Nanomedicine 2025 accessed 11 Nov 2026
  24. 24Pharmaceutics 2026 accessed 11 Nov 2026
  25. 25Int J Mol Sci 2025 accessed 11 Nov 2026
  26. 26Crit Rev Ther Drug Carrier Syst 2022 accessed 11 Nov 2026
  27. 27Adv Exp Med Biol 2018 accessed 11 Nov 2026
  28. 28Int J Pharm 2023 accessed 11 Nov 2026
  29. 29Peptency lab results and certificate of analysis page accessed 11 Nov 2026
  30. 30J Control Release 2025 accessed 11 Nov 2026
  31. 31Int J Pharm 2016 accessed 11 Nov 2026
  32. 32Regulation (EC) No 1223/2009, Article 2, as retained on legislation.gov.uk accessed 11 Nov 2026
  33. 33MHRA, borderline products guidance for Great Britain accessed 11 Nov 2026
  34. 34AAPS PharmSciTech 2020 accessed 11 Nov 2026
  35. 35J Pharm Anal 2015 accessed 11 Nov 2026

About this page

Research-use information. This library summarises published literature and regulator records. It is not guidance for use, not medical advice, and not a statement that any material is suitable for use in people or animals.

Reviewed by the Peptency editorial process. Version 1, edited 11 November 2026, 35 sources.

Cite this page: Peptency Academy. Peptide patches: transdermal and microneedle delivery in research. Version 1./eu/academy/guides/peptide-patches-transdermal-microneedle-research/